FDA’s Augment Letter May Force Wright to Rewrite Turnaround Story

To the surprise of many, the FDA issued a “not approvable” letter to Wright Medical Group for its Augment biologic bone graft. Now company executives must figure out what to do next to grow in the extremities space.

More from Archive

More from In Vivo